Effects of Captopril on Sympathetic Activity, Lipid and Carbohydrate Metabolism in a Model of Obesity-Induced Hypertension in Dogs
Abstract
Ten age-matched beagle dogs were kept on a high-fat diet and followed for 12 weeks. During this period the animals were divided into two groups (n = 5), either with or without oral captopril treatment. Dogs were tested periodically for biochemical and clinical parameters, and at the end of the study animals were killed and thoracic aorta samples were obtained for histologic evaluation. From the third week, the captopril group presented significantly lower values of mean arterial pressure, plasma norepinephrine, and fasting glucose and cholesterol levels than those attained in the nontreated group. Furthermore, aorta samples from untreated animals showed profuse staining for fat content at the intima and adventitia layers, while this reaction was restricted to the outer layer in treated dogs. These data suggest that the beneficial effects of captopril therapy in this obesity-induced hypertension model could be based on blood pressure control, together with reduction of serum glucose, cholesterol, and sympathetic activity levels. In addition, captopril treatment could play a role in the retardation of the early stages of vascular atherogenetic lesion.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
An important role for AngII in stimulating renal NaCl reabsorption and in mediating obesity hypertension is supported by studies in experimental animals demonstrating that AngII receptor blockade or ACE inhibition attenuates sodium retention, volume expansion, and increased BP in obesity.
“An important role for AngII in stimulating renal NaCl reabsorption and in mediating obesity hypertension is supported by studies in experimental animals demonstrating that AngII receptor blockade or ACE inhibition attenuates sodium retention, volume expansion, and increased BP in obesity43,44.”
From Obesity-Induced Hypertension: Interaction of Neurohumoral and Renal Mechanisms (2015) · cites this paper as [44]
Cited by
Sorted by citations
Obesity-Induced Hypertension: Interaction of Neurohumoral and Renal Mechanisms
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2015) · Circulation Research · doi:10.1161/circresaha.116.305697 · Cited by 1,360 · see citing works
The Kidney, Hypertension, and Obesity
Hall, J. E. (2003) · Hypertension · doi:10.1161/01.hyp.0000052314.95497.78 · Cited by 868 · see citing works
Obesity, hypertension, and chronic kidney disease
Hall, J., Juncos, L., Wang, Z., Hall, M., do Carmo, J., & da Silva, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s39739 · Cited by 520 · see citing works
Obesity hypertension: role of leptin and sympathetic nervous system
Hall, J. E. (2001) · American Journal of Hypertension · doi:10.1016/s0895-7061(01)02077-5 · Cited by 361 · see citing works
Hypertension: Physiology and Pathophysiology
Hall, J. E., Granger, J. P., do Carmo, J. M., da Silva, A. A., Dubinion, J., George, E., Hamza, S., Speed, J., & Hall, M. E. (2012) · Comprehensive Physiology · doi:10.1002/cphy.c110058 · Cited by 232 · see citing works
Mechanisms of Hypertension and Kidney Disease in Obesity
HALL, J. E., BRANDS, M. W., & HENEGAR, J. R. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07788.x · Cited by 222 · see citing works
Mechanisms of Abnormal Renal Sodium Handling in Obesity Hypertension
Hall, J. (1997) · American Journal of Hypertension · doi:10.1016/s0895-7061(97)00075-7 · Cited by 213 · see citing works
Aldosterone Antagonism Attenuates Obesity-Induced Hypertension and Glomerular Hyperfiltration
de Paula, R. B., da Silva, A. A., & Hall, J. E. (2004) · Hypertension · doi:10.1161/01.hyp.0000105624.68174.00 · Cited by 207 · see citing works
Pathophysiology of obesity hypertension
Hall, J. E. (2000) · Current Hypertension Reports · doi:10.1007/s11906-000-0073-4 · Cited by 185 · see citing works
Role of sympathetic nervous system and neuropeptides in obesity hypertension
Hall, J. E., BRANDS, M., Hildebrandt, D. A., Kuo, J. J., & Fitzgerald, S. M. (2000) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2000000600001 · Cited by 149 · see citing works
“Three additional observations suggest a role for Ang II in stimulating sodium reabsorption, shifting pressure natriuresis, and causing hypertension in obesity: 1) treatment with an Ang II antagonist blunted sodium retention, volume expansion, and increased arterial pressure associated with a chronic high fat diet in d…”
BackgroundObesity-hypertension: an ongoing pandemic
Francischetti, E. A., & Genelhu, V. A. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01262.x · Cited by 130 · see citing works
ABNORMAL KIDNEY FUNCTION AS A CAUSE AND A CONSEQUENCE OF OBESITY HYPERTENSION
Hall, J. E., Brands, M. W., Henegar, J. R., & Shek, E. W. (1998) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1998.tb02146.x · Cited by 108 · see citing works
Obesity, essential hypertension and renin–angiotensin system
Segura, J., & Ruilope, L. M. (2007) · Public Health Nutrition · doi:10.1017/s136898000700064x · Cited by 95 · see citing works
Self-citationNondiabetic consequences of obesity on kidney
Srivastava, T. (2006) · Pediatric Nephrology · doi:10.1007/s00467-006-0027-4 · Cited by 88 · see citing works
“Blood pressure elevation is blunted by angiotensin II antagonist or ACE inhibitors in both obese dogs and humans [38, 39].”
BackgroundRenal denervation for the treatment of resistant hypertension: review and clinical perspective
Iliescu, R., Lohmeier, T. E., Tudorancea, I., Laffin, L., & Bakris, G. L. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00246.2015 · Cited by 50 · see citing works
“Other studies in experimental animals show that ANG II blockade or angiotensin-converting enzyme (ACE) inhibition attenuates sodium retention, volume expansion, and increased arterial pressure in obesity (8, 73).”
Choi, J.-H., Park, S., Kwon, T. K., Sohn, S., Park, K. M., & Kim, J. I. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.166 · Cited by 50 · see citing works
Sušić, D., & Varagić, J. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.08.008 · Cited by 43 · see citing works
Angiotensin II and neurohumoral control of the renal medullary circulation
Evans, R. G., Head, G. A., Eppel, G. A., Burke, S. L., & Rajapakse, N. W. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05233.x · Cited by 37 · see citing works
Factors Responsible for Obesity-Related Hypertension
Lim, K., Jackson, K. L., Sata, Y., & Head, G. A. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0750-1 · Cited by 35 · see citing works
Hypertension: Physiology and Pathophysiology
Hall, J. E., Granger, J. P., do Carmo, J. M., da Silva, A. A., Dubinion, J. H., George, E. M., Hamza, S., Speed, J. S., & Hall, M. E. (2012) · Comprehensive physiology · doi:10.1002/j.2040-4603.2012.tb00470.x · Cited by 32 · see citing works
Hall, M. E., & Hall, J. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00005-6 · Cited by 33 · see citing works
Özbek, L., Abdel‐Rahman, S. M., Unlu, S., Güldan, M., Copur, S., Burlacu, A., Covic, A. C., & Kanbay, M. (2024) · Medicina · doi:10.3390/medicina60101668 · Cited by 22 · see citing works
“Furthermore, many clinical observations and animal studies identified increased RAAS activation in obesity [121,122].”
BackgroundBrands, M. W., Bell, T. D., Rodriquez, N. A., Polavarapu, P., & Panteleyev, D. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90528.2008 · Cited by 18 · see citing works
“However, although there is good evidence that the renin-angiotensin-aldosterone and sympathetic nervous systems contribute to sodium retention and hypertension in metabolic syndrome (8, 10, 21, 27, 33), there remains no direct evidence outside of experimental models in rats that the hyperinsulinemia or impaired glucos…”
BackgroundRenal Angiotensin II Receptors, Hyperinsulinemia, and Obesity
Hussain, T. (2003) · Clinical and Experimental Hypertension · doi:10.1081/ceh-120024983 · Cited by 18 · see citing works
“Treatment of obese dogs and obese humans with ACE inhibitors and=or AT1 receptor blockers (ARB) reduces sodium retention and decreases blood pressure (43,44).”
BackgroundSerum Lipid Physiology and the Influence of Glaucoma Medications
Stewart, W. C., & Osterman, J. (1998) · Survey of Ophthalmology · doi:10.1016/s0039-6257(98)00030-7 · Cited by 17 · see citing works
Pathophysiology of Obesity—Induced Hypertension and Target Organ Damage
Hall, J. E., da Silva, A. A., Brandon, E. L., Stec, D. E., Ying, Z., & Jones, D. W. (2007) · Elsevier eBooks · doi:10.1016/b978-0-323-03961-1.50041-6 · Cited by 17 · see citing works
Cardioprotective Role of Captopril: From Basic to Applied Investigations
Stoiljkovic, M., Jakovljevic, V. L., Milosavljević, J., Bolevich, S., Jeremic, N. S., Čanović, P. P., Фисенко, В. П., Tikhonov, D. A., Крылова, И. Н., Bolevich, S. S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157215 · Cited by 11 · see citing works
Primary and Secondary Hypertension
Blumenfeld, J., Liu, F., & Laragh, J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10046-6 · Cited by 11 · see citing works
Villa, E., Rabano, A., Albarran, O. G., Ruilope, L. M., & Garcia-Robles, R. (1998) · American Journal of Hypertension · doi:10.1016/s0895-7061(98)00053-3 · Cited by 11 · see citing works
“The control group was maintained throughout the study with a normal diet, whereas the 15 remaining animals were kept on a high-fat diet consisting of beef and lard in addition to the regular food, as previously reported.(10) The Obese group received no pharmacologic therapy during the study, whereas the Capto group wa…”
BackgroundMethodSelf-citationIntrarenal Ghrelin Receptor Antagonism Prevents High-Fat Diet-Induced Hypertension in Male Rats
Kemp, B. A., Howell, N. L., Gildea, J. J., & Padia, S. H. (2014) · Endocrinology · doi:10.1210/en.2013-2177 · Cited by 10 · see citing works
Effects of Hyperinsulinemia on vascular blood flows in experimental obesity
Villa, E., González-Albarrán, O., Rábano, A., & García‐Robles, R. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(99)00045-x · Cited by 9 · see citing works
Self-citationObesity and Metabolic Syndrome Hypertension
Hall, M. E., Wang, Z., do Carmo, J. M., Kamimura, D., & Hall, J. E. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-59918-2_42 · Cited by 8 · see citing works
Obesity-Associated Hypertension
Uwaifo, G. (2013) · Humana Press eBooks · doi:10.1007/978-1-60761-548-4_13 · Cited by 39 · see citing works
Obesity and Hypertension: Impact on Cardiovascular and Renal Systems
Hall, J. E., Jones, D. W., Kuo, J. J., da Silva, A. A., Liu, J., & Tallam, L. S. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0258-5.50134-4 · Cited by 1 · see citing works
Majewski, C., & Bakris, G. L. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_5-2 · Cited by 1 · see citing works
Obesity, insulin resistance, and the renal circulation
Hall, J. E., Brands, M. W., Shek, E. W., & Henegar, J. R. (2000) · Advances in organ biology · doi:10.1016/s1569-2590(00)09076-5
Secondary Causes: Work-Up and Its Specificities in CKD: Influence of Autonomic Dysfunction
Iliescu, R., & Șerban, D. N. (2017) · Springer eBooks · doi:10.1007/978-3-319-56827-0_10
Majewski, C., & Bakris, G. L. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_5-1
Majewski, C., & Bakris, G. L. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_5
Majewski, C., & Bakris, G. L. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_5
Félix, C. S., Ibarra, K. J. V., Angulo-Camacho, J. Á., & Ibarra-Sánchez, A. (2024) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v8i1.9474
10.1016/b978-1-4160-3105-5.50044-x
(2000) · Time to knit · doi:10.1016/b978-1-4160-3105-5.50044-x
- Authors
- Robles, R. G., Villa, E., Santirso, R., Martinez, J., Ruilope, L. M., Carmen, C., & Sancho, J. M.
- Affiliations
- Hospital Universitario Ramón y Cajal (ES)
- Corresponding author
- Robles, Rafael G.
- ORCID
- Ruilope, Luis M.
- Venue
- American Journal of Hypertension
- Publisher
- Oxford University Press (OUP)
- Published
- 1993-12
- Volume
- 6
- Issue
- 12
- Pages
- 1009-1015
- ISSN
- 0895-7061 (ISSN-L)
- 1941-7225
- OpenAlex
- W2467042522
- Cited by
- 42
- References
- 0
- Citations by year
- 2025: 1 · 2024: 2 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 1 · 2015: 2 · 2014: 2 · 2012: 4
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Hypertension (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- captopril, obesity-related hypertension, sympathetic activity, plasma norepinephrine, lipid metabolism, carbohydrate metabolism, high-fat diet, atherosclerosis, blood pressure control, cholesterol, fasting blood glucose, ACE inhibitors
- MeSH terms
- Animals, Blood Glucose, Captopril, Cholesterol, Dogs, Hemodynamics, Hypertension, Kidney, Norepinephrine, Obesity, Sympathetic Nervous System, Carbohydrate Metabolism, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
